Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial.
Dai Z, Zhu R, Sheng Z, Qin G, Luo X, Qin Q, Song C, Li L, Jin P, Yang G, Cheng Y, Peng D, Zou C, Wang L, Shentu J, Zhang Q, Zhang Z, Yan X, Fang P, Yan Q, Yang L, Fan X, Liu W, Wu B, Cui R, Wu X, Xie Y, Shu C, Shen K, Wei W, Lu W, Chen H, Zhou Z.
Dai Z, et al.
Front Endocrinol (Lausanne). 2023 Apr 5;14:1168757. doi: 10.3389/fendo.2023.1168757. eCollection 2023.
Front Endocrinol (Lausanne). 2023.
PMID: 37091850
Free PMC article.
Clinical Trial.